Tectonic Therapeutic (TECX) shares climbed 90% in Thursday's premarket session after the company said a phase 1b trial showed that TX45 improved left ventricular function and pulmonary hemodynamics.
The biotech firm said TX45 was well tolerated with no serious or severe adverse events, discontinuations, infusion reactions, or drug-related adverse events.
"These interim results show that TX45 achieved improvements in hemodynamics which met and exceeded our prespecified objectives," Chief Executive Alise Reicin said in a release.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.